Results 91 to 100 of about 54,753 (257)
Abstract Seizure frequency has been the primary endpoint in epilepsy trials, with enrollment usually requiring ≥4 seizures per month. This threshold is more and more misaligned with clinical reality, as the availability of more treatment options has reduced baseline seizure burden, with a risk of excluding a proportion of patients from trials. Although
Stéphane Auvin, Jacqueline French
wiley +1 more source
Abstract Objective This study was undertaken to evaluate whether seizure freedom in pregnancy predicts seizure freedom in the postpartum period in women with epilepsy (WWE). Prior studies have shown that seizure freedom prior to conception strongly predicts seizure freedom during pregnancy.
Emma C. Osterhaus +7 more
wiley +1 more source
Abstract Children with developmental and epileptic encephalopathies (DEEs) face cognitive and behavioral challenges that may have a greater impact than seizures on their quality of life (QoL). The need to assess these nonseizure outcomes for evaluating treatments is increasingly recognized.
Cinzia Correale +9 more
wiley +1 more source
Tonic–clonic seizures captured during ambulatory video‐EEG are frequently unreported
Abstract Objective Tonic–clonic seizures (TCSs) are widely regarded as clinically obvious, yet seizure counts used for treatment decisions and risk counseling often rely on patient or caregiver diaries. We sought to quantify the frequency of unreported TCSs during prolonged ambulatory video‐EEG (vEEG) monitoring and examined associations with ...
Ewan S. Nurse +3 more
wiley +1 more source
Pediatric toe-walking cohort with heterozygous SBF1 variants: A phenotypic description
Purpose: Persistent toe walking is frequently labeled idiopathic; however, targeted genetic testing in selected cohorts can identify variants in genes implicated in neuromuscular disease.
David Pomarino +4 more
doaj +1 more source
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer +7 more
wiley +1 more source
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer +7 more
wiley +1 more source
This graphical abstract provides an overview of the content from this open‐label extension study of fenfluramine use in patients with Dravet syndrome or Lennox‐Gastaut syndrome. Abstract Objective Long‐term safety and global functioning are reported in patients with Dravet syndrome (DS) or Lennox–Gastaut syndrome (LGS) treated with fenfluramine in an ...
Antonio Gil‐Nagel +18 more
wiley +1 more source
Consideration of the issue of the application of the principle of Free Prior and Informed Consent (FPIC) to resources sector projects affecting Australian Indigenous Peoples in the context of meaningful stakeholder engagement (MSE) requires some preliminary consideration of the notion of MSE.
openaire +3 more sources
A prospective natural history study protocol for clinical trial readiness in synaptic disorders
Abstract Objective STXBP1‐related disorder (STXBP1‐RD) and SYNGAP1‐related disorder (SYNGAP1‐RD) are two common genetic synaptopathies that are associated with epilepsy, developmental delay, intellectual developmental disorder, and behavioral problems.
Jillian L. McKee +38 more
wiley +1 more source

